about
Poor agreement of objectively measured and self-reported physical activity in juvenile dermatomyositis and juvenile systemic lupus erythematosus.Reduced Aerobic Capacity and Quality of Life in Physically Inactive Patients With Systemic Lupus Erythematosus With Mild or Inactive Disease.The design and rationale of an interdisciplinary, non-prescriptive, and Health at Every Size®-based clinical trial: The "Health and Wellness in Obesity" study.Physical (in)activity and its influence on disease-related features, physical capacity, and health-related quality of life in a cohort of chronic juvenile dermatomyositis patients.Objectively measured physical activity and its influence on physical capacity and clinical parameters in patients with primary Sjögren's syndrome.Parathyroid Hormone Secretion Is Controlled by Both Ionized Calcium and Phosphate During Exercise and Recovery in Men.Poor muscle strength and function in physically inactive childhood-onset systemic lupus erythematosus despite very mild diseaseTackling Youth Inactivity and Sedentary Behavior in an Entire Latin America CityPrescribed Versus Preferred Intensity Resistance Exercise in Fibromyalgia PainChronotropic Incompetence and Reduced Heart Rate Recovery in Rheumatoid ArthritisEffects of a new intervention based on the Health at Every Size approach for the management of obesity: The "Health and Wellness in Obesity" study"Despite being an athlete, I am also a human-being": Male elite gymnasts' reflections on food and body imageEffects of health at every size® interventions on health-related outcomes of people with overweight and obesity: a systematic reviewEating Pleasure in a Sample of Obese Brazilian Women: A Qualitative Report of an Interdisciplinary Intervention Based on the Health at Every Size ApproachCreatine Supplementation (3 g/d) and Bone Health in Older Women: A 2-Year, Randomized, Placebo-Controlled Trial"I put it in my head that the supplement would help me": Open-placebo improves exercise performance in female cyclistsCombating physical inactivity during the COVID-19 pandemic
P50
Q40829949-C689B7AF-7F6B-49BF-81A5-20C73D6C4D77Q44965545-4EBE0A83-97A0-460A-B686-072ED352191AQ47174578-7DA1C146-0C52-47F4-9887-44901EF0CC8AQ47765966-E288AA20-7D29-4275-B1A2-04B34699F58AQ48037669-7789828E-6625-4D87-956A-2ECA92E63C74Q51294534-177BF058-5834-42A0-8CD9-A0A119672F63Q57537508-BAAD266D-BADA-4103-8573-3409A6925160Q58122923-64C9D62C-D657-497E-9245-57CB0E4C443AQ58789793-2AB1FBB0-E8A8-490E-9C36-4E41CD686EA0Q88616025-95D829D2-3DC7-4634-8621-46F2AFC1D820Q89445379-3B85280F-FAEF-41B4-A9CE-439E28BB8FFEQ90777089-F08CC97A-CBEB-4F92-BA85-D9D327C7417AQ91814725-EE8FFCA1-2E8B-4475-9A0E-CDB5A6DBB3FCQ92798977-44AC5FE9-9812-4044-BC72-04707E42D4FDQ93140078-20DF346B-5A80-4809-95DB-86CD1182C52BQ94069677-E6B4DFAF-0763-49E0-82E4-51A7553A73A9Q94474394-C09619D7-DDB0-4168-8D82-A7928A101EBA
P50
description
researcher ORCID ID = 0000-0002-1363-7233
@en
wetenschapper
@nl
name
Ana J Pinto
@ast
Ana J Pinto
@en
Ana J Pinto
@es
Ana J Pinto
@nl
type
label
Ana J Pinto
@ast
Ana J Pinto
@en
Ana J Pinto
@es
Ana J Pinto
@nl
prefLabel
Ana J Pinto
@ast
Ana J Pinto
@en
Ana J Pinto
@es
Ana J Pinto
@nl
P21
P31
P496
0000-0002-1363-7233